Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer

Maurizio Scaltriti(Memorial Sloan Kettering Cancer Center), José Baselga(Universitat Autònoma de Barcelona)
Molecular Cancer Therapeutics
March 8, 2011
10.1158/1535-7163.mct-10-0966
Cited by 52

Related Papers

Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
|JNCI Journal of the National Cancer Institute|2007|876
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
|Journal of Clinical Oncology|2005|409
Targeted therapies for breast cancer
|Journal of Clinical Investigation|2011|371
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
|Clinical Cancer Research|2004|277
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
|Cancer Cell|2016|228